

# 17

## Literatura

1. *Abate, P., Pepino, M.Y., Dominguez, H.D., Spear, N.E., Molina, J.C.:* Fetal associative learning mediated through maternal alcohol intoxication. *Alcohol Clin Exp Res.* 2000 Jan;24(1), s. 39–47.
2. *Arthur, W.K., Chan:* Effects of combined alcohol and benzodiazepine: a review *Drug and Alcohol Dependence.* 13 (1984), s. 315–341.
3. *Baar, A., Soepatmi, S., Gunning W., Akkerhuis G.:* Development after prenatal exposure to cocaine, heroin; and methadon. *Acta Paediatr. Suppl*, 404, 1994, s. 4046.
4. *Baller, K.:* Office for children of drug- addicted parents. *Acta Paediatr Suppl* 404, 1994, s. 75–77.
5. *Bauer, Ch.:* Perinatal effects of prenatal drug exposure – neonatal aspects. *Clinics in Perinatology*, 26, 1, 1999, 3, s. 87–106.
6. *Bean, X.:* Maternal substance abuse. In: *Shaffer and Averys: Diseases of the newborn sixth ed.* Philadelphia 1991, Saunders, s. 243–253.
7. *Behnke, M., Eyler, F., Conlon, M., Wobie, K., Woods, N., Cumming, W.:* Incidence and description of structural brain abnormalities in newborns exposed to cocaine. *The J of Pediatrics* 132, 2, 1998, s. 291–294.
8. *Belcheva, M., Bohn, L., Ho, M., Johnson, F., Yanai, J., Barron, S., Coscia, C.:* Brain opioid receptor adaptation and expresion after prenatal exposure to buprenorphine. *Developmental Brain Research* 111, 1998, s. 35–42.
9. *Bentur, Y.:* Acute poisoning in pregnancy, Harefuah. 2001 Aug;140(8):770–5. Review. Hebrew.
10. *Bishai, R., Koren, G.:* Maternal and obstetric effects of prenatal drug exposure. *Clinics in Perinatology* 26, 1, 1999, 3, s. 75–106.
11. *Blinick, G., Wallach, R. C., Jerez, E. et al.:* Drug addiction in pregnancy and the neonate. *Am j. Obstet Gynecol*, 125, 1976, s. 135.
12. *Blum, K., Noble, E.P., Sheridan, P.J.:* Allelic asociation of human dopamine D2 receptor gene in alcoholism. *J Amer Med Assoc*, 263, 1990, s. 2055–2060.
13. *Brown, H.L., Britton, K.A., Mahaffey, D., Brizendine, E., Hiatt, A.K., Turnguert, M.A.:* Metadone maitenance in pregnancy: A Reappraisa. *Am J Obst Gyn*, 179, 2, 1998, s. 459–463.

14. Burkett, G., Gomez-Marin, O., Yasin, S.Y., Matinez, M.: Prenatal Care in Cocaine-Exposed Pregnancies, *Obstetrics and Gynecology*, 92, 2, 1998, s. 193–200.
15. Burkett, G., Yasin, S., Oalow, D.: Perinatal Implications of Cocaine Exposure. *J of Reproductive Medicine*, 35, 1, 1990, s. 35–42.
16. Callahan, C. et al.: Measurement of gestational cocaine exposure: Sensitivity of infant's hair, meconium, and urine. *J Pediatr*. 120, 5, 1992, s. 763–768.
17. Campbell, T.A., Collins, K.A.: Pediatric toxicologic deaths: a 10-year retrospective study, *Am J Forensic Med Pathol*. 2001 Jun;22(2), s. 184–7.
18. Cejtin, H.E., Young, S. A., Ungaretti, J., Anciaux, D., Imam, S., Teopengco, E., Smiler, C. M.: Effect of cocaine on the placenta. *Pediatr Dev Pathol*, 2, 1999, s. 143–147.
19. Cejtin, H. E., Young, S. A., Ungaretti, J., Anciaux, D., Imam, S., Teopengco, E., Smiler, C. M.: Effect of cocaine on the placenta. *Pediatr Dev Pathol*, 2, 2, 1999, s. 143–147.
20. Chao, C.R.: Cardiovascular Effects of Cocaine During Pregnancy. *Seminars in Perinatology*, 20, 2, 1996, s. 107–114.
21. Chasnoff, L.: Newborn Infants with Drug Withdrawal Symptoms. *Pediatrics in review*, 9 1998, s. 273–277.
22. Chazotte, C., Youchah, J., Comerford Freda, M.: Cocaine use during pregnancy and low birth weight: The impact of prenatal care and drug treatment. *Seminars in perinatology*, 19, 4, 1995, s. 293–300.
23. Chiriboga, C., Brust, J., Bateman, D., Hauser, A.: Dose-response effect of fetal cocaine exposure on newborn neurologic function. *Pediatrics*, 103,1, 1999, s. 79–82.
24. Coleman, F., Kay, B.: Biology of addiction. Substance abuse in pregnancy, *Obstetrics and Gynecology clinics of North America*, 25, 1, 1998, s. 1–20.
25. Collins, E., Hardwick, R.J., Jeffery, H.: Perinatal cocaine intoxication, *med J Aust*. 1989 Mar 20, 150 (6), s. 331–2, 334.
26. Csémy, L., Lejčková, P., Sadílek, P., Sovinová, H.: Evropská školní studie o alkoholu a jiných drogách (ESPAD). Výsledky průzkumu v České republice v roce 2005. Praha, 2004.
27. Cushman, P., jr.: Growth hormone in narcotic addiction. *J Clin Endocrinol Metab*. 35, 1972, s. 352.
28. Czeizel, A.E., Timar, L., Susanszky, E.: Timing of suicide attempts by self-poisoning during pregnancy and pregnancy outcomes., *Int J Gynaecol Obstet*. 1999 Apr;65(1), s. 39–45.
29. Czeizel, A.E., Tomcsik, M., Timar, L.: Teratologic evaluation of 178 infants born to mothers who attempted suicide by drugs during pregnancy, *Obstet Gynecol*. 1987 Aug, 90 (2), s. 195–201.
30. Dashe, J.S., Jackson, G.L., Olscher, D. A., Zane, E. H., Wendel G.D.: Opioid detoxification in pregnancy. *Obstetrics and Gynecology* 92, 5, 1998, s. 854–858.
31. Delgado-Iribaren, A., Calvo, M., Perez, A., del Alamo, M., Cercenado, S.: Intravenous drug users serologic control: what may be prevented. *Enferm Infecc Microbiol Clin*, 18, 1, 2000, s. 2–5.

32. DeVille, K., Kopelman, L.: Moral and social issues regarding pregnant women who use and abuse drugs. *Obstetrics and gynecology clinics of North America*, Substance abuse in pregnancy. 25, 1, 1998, s. 237–254.
33. Doberczak, T.M., Kandall, S.R., Friedmann, P.: Relationship between maternal methadone dosage, maternal-neonatal methadone levels, and neonatal withdrawal. *Obstet Gynecol*, 81, 6, 1993, s. 936–940.
34. Drábková, J.: *Medicína naléhavých a kritických stavů*, Institut pro další vzdělávání pracovníků ve zdravotnictví, Brno, 1992.
35. Edmondson, R., Smith, T.: Temperament and behavior of infants prenatally exposed to drugs: Clinical implications for the mother-infant dyad. *Infant Mental Health J* 15, 1994, s. 368–379.
36. Eisen, L.N., Field, T.M., Bandstra, E. et al.: Perinatal cocaine effects on neonatal stress behavior and performance on the Brazelton Scale. *Pediatrics* 88, 1991, s. 477–480.
37. Eriksson, M., Zetterstrom, R.: Amphetamine addiction during pregnancy: 10-year follow-up. *Acta Paediatr. Suppl.* 1994, 404, s. 27–31.
38. Erskine, L.R., Ritchie, J.W.: The effects of maternal consumption of alcohol on human umbilical artery blood flow. *Am J Obstet Gynecol*, 154, 1986, s. 318.
39. Eyler, F., Behnke, M.: Early development of infants exposed to drugs prenatally. *Clinics in Perinatology*, 26, 1, 1999, 3, s. 107–150.
40. Fergusson, D.M. et al.: Maternal use of cannabis and pregnancy outcome. *BJOG* 2002 Jan;109(1), s. 21–27.
41. Finnegan, L.P.: Prenatal drug exposure. In: *Clinical manual of substance abuse*. Second ed. Philadelphia, Mosby 1996, s. 257–271.
42. Fischer, G. et al.: Approaches to the management of pregnant drug misusers. In: *Pregnancy and drug misuse*. Council of Europe Publishing Strasbourg, 1998, s. 1525.
43. Fisher, S.E., Atkinson, M., Van Thiel, D.H.: Selective fetal malnutrition: The defects of nicotine, ethanol and acetaldehyde upon in vivo uptake of alpha-amino butyric acid by human term placental villous slices. *Dev Pharmacol Ther*, 7, 1984, s. 229.
44. Fishman, R.H., Yanai, J.: Long-lasting effects of early barbiturates on central nervous system and behavior. *Neurosci Biobehav Rev*, 7, 1983, s. 19.
45. Frasca, J., Orav, J., Walsch, E., Lipschultz, S.: Arrhythmias in Children Prenatally Exposed to Cocaine. *Arch Pediatr Adolesc Med*, 148, 11, 1994, s. 1163–1169.
46. Fulroth, R., Phillips, B., Duranc, D.J.: Perinatal outcomes of infants exposed to cocaine and/or heroin in utero. *Am J Dis Child*, 143, 1989, s. 905–910.
47. Goldberger, A.: *Opiates, Abused drugs monograph series*, Abbott Laboratories, Texas: Irving, 1994, s. 24.
48. Green, M.: The Neonatal Narcotic Withdrawal Index: A Device for the Improvement of Care in the Abstinence Syndrome. *Am.J. Drug Alcohol Abuse*, 8, 2, 1981, s. 203–213.

49. Hadeed, A., Siegel, S.: Maternal cocaine use during pregnancy: Effect on the newborn infant. *Pediatrics*, 84, 2, 1989, s. 205–210.
50. Halmesmaki, E. et al.: Alpha – fetoprotein, human placental lactogen, and pregnancy – specific beta 1-glycoprotein in pregnant women who drink: relation to fetal alcohol syndrome. *Am J Obstet Gynecol* 1986 Sep;155(3), s. 598–602.
51. Handler, A., Kisten, N., Davis, F.: Cocaine use during pregnancy: Perinatal outcomes. *Am J Epidemiol* 133, 8, 1991, s. 818–825.
52. Hans, L.: Demographic and psychosocial characteristics of substance – abusing pregnant women. *Clinics in Perinatology*, 26, 1, 1999, 3, s. 55–74.
53. Hojer, J., Baehrendtz, S., Matell, G., Gustafsson, L.L.: Diagnostic utility of flumazenil in coma with suspected poisoning: a double blind, randomised controlled study. *BMJ*. 1990 Dec 8, 301(6764), s. 1308–11.
54. Horáček et al.: Psychotické stavy v terapeutické praxi, s. 179–190.
55. Howard, C., Lawrence, R.: Drugs and breastfeeding. *Clinics in Perinatology*, 26, 2, 1999, 6, s. 447–47.
56. Hulse, G., Milne, E., English, D., Holman C.: The relationship between maternal use of heroin and methadon and infant birth weight. *Addiction* 92, 11, 1997, s. 1571–1579.
57. Jacobson, S.W, Chiodo, L.M., Sokol, R.J., Jacobson, J.L.: Validity of maternal report of prenatal alcohol, cocaine, and smoking in relation to neurobehavioral outcome. *Pediatrics* 2002 May;109(5), s. 815–825.
58. Jarvis, M., Schnoll, S.: Methadon use during pregnancy. In Medications Development for the Treatment of Pregnant Addicts and their Infant. NIDA Research monograph Series 149, Rockville, Fishers Lane, 1995, s. 1–4.
59. Kalina, K. et al.: Drogy a drogové závislosti. Mezioborový přístup, 2003.
60. Kaltenbach, K., Finnegan, L.: Neonatal abstinence syndrome, pharmacotherapy and developmental outcome, *Neurobehav Toxicol Teratol*, 4, 8, 1986, s. 353–355.
61. Kandall, S.R.: Fetal and neonatal effects of maternal disease. *Clinics in Perinatology*, 30, 3, 1994, s. 283–285.
62. Kandall, S.R.: Medications Development for the Treatment of Pregnant Addicts and Their Infants, National Institute on Drug Abuse Research, monograph series 149, Fishers Lane Rockville, 1995.
63. Kandall, S., Doberczak, T., Jantunen, M., Stein, J.: The Methadon – maintained pregnancy. *Clinics in Perinatology*, 26, 1, 1999, 3, s. 173–183
64. Kandall, S.: Treatment strategies for drug – exposed neonates. *Clinics in Perinatology*, 26, 1, 1999, 3, s. 231–243.
65. Katikanneni, LD., Sallee, FR., Ibrahim, HO et al.: Neonatal Hair analysis for benzoylecgonine: A marker for gestational cocaine exposure, growth at birth, and neurodevelopment based on short-term follow-up (4 to 8 months). US Department of Health and Human Services, 1995, s. 362.
66. Killam, K.F., Olds, J., Sinclair, J.: Further studies on the effects of centrally acting drugs on the results of self-stimulation. *J Pharmacol Exp Ther*, 119, 1957, s. 157–163.

67. King, T., Perlman, J., Laptook, A., Rollins, N., Jackson, G., Little, B.: Neurologic manifestation of utero cocaine exposure in near-term and term infants. *Pediatrics*, 96, 1995, 2, s. 259–263.
68. Koller, F., Nagel, G.A., Neuhaus, K. a kol.: *Naliehavé situácie vo vnútornom lekárstve*, Osveta. Martin, 1982.
69. Konkol, J.: Is there a cocain baby syndrome? *J Child Neurol.*, 9, 3, 1994, s. 225–226.
70. Koob, G.F., Markou, A., Weiss, F., Shulteis, G.: Opponent process and drug dependence. Neurobiological mechanisms. *Semin Neurosci*, 5, 1993, s. 351–358.
71. Kopp, W., Vogel, M.: Histologische und morphometrische Plazentabefunde bei Heroinsucht der Mutter. *Geburtshilfe Perinatol*, 186, 1982, s. 37–40.
72. Kučera, J., Kubelík, J., Melichar, J., Štembera, Z., Velebil, P., Kučerová, I.: Nové tabulky normální porodní hmotnosti v České republice. *Čes.-slov. Pediat*, 54, 10, 1999, s. 572–578.
73. Kučera, J., Kubelík, J., Melichar, J., Štembera, Z., Velebil, P., Kučerová, I.: Analýza distribuce hodnot porodních hmotností novorozenců v ČR. *Neonatal Listy*, 3, 4, 1997, s. 257–263.
74. Landesman, S.H., Willoughby, A.: HIV disease in reproductive age women: A problem of the present. *JAMA*, 261, 1989, s. 1326.
75. Lifschitz, M.H., Wilson, G.S., Smith, E.O., Desmond, M.M.: Fetal and postnatal growth of children born to narcotic-dependent women. *J Pediatr* 102, 5, 1983, s. 686–691.
76. Little, B., Van Beveren, T.: Placental transfer of selected substances of abuse. *Seminars in Perinatology*, 20, 2, 1996, s. 147–153.
77. Maitra, R.: Psychotropic drugs and lactation. *The New Zealand Medical Journal* Vo.109, 1996, s. 217–219.
78. Majid, A., Holnes, R., Desselberger, V., Sinimond, P., McKee, T.A.: Molecular epidemiology of hepatitis C virus infection amongst intravenous drugs users in rural communities. *J Med Virol.* 46, 1, 1995, s. 48–51.
79. Malanga, C., Kosofsky B.: Mechanism of action of drugs of abuse on the developing brain. *Clinics in Perinatology*, 26, 1, 1999, 3, s. 17–37.
80. Markou, A., Weiss, F., Gold, L.H., Caine, S. B., Shulteis, G., Koob, G.F.: Animal models of drug craving. *Psychopharmacology*, 112, 1998, s. 63–182.
81. Marquet, P. et al.: Buprenorphine withdrawal syndrome in a newborn. *Clinical pharmacology & therapeutics*, 62, 5, 1999, s. 569–571.
82. Martinez, A., Larrabee, R., Monga, M.: Cocaine is associated with intrauterine fetal death in women with suspected preterm labor. *Am J Perinat.*, 13, 3, 1996, s. 163–166.
83. Mass, U., Kattner, E., Weingard-Jesse, B., Schäfer, A., Obladen, M.: Infrequent neonatal opiate withdrawal following maternal methadone detoxification during pregnancy. *J. Perinat. Med.* 18, 1990, s. 111–118.
84. Meyer, R.E.: The disease called addiction: emerging evidence in a 200-year debate. *The Lancet*, 347, 20, 1996, s. 162–166.

85. Mitchell, J.L.: Pregnant Substance – Using Women, Treatment Improvement Protocol TIP Series, 2, Fishers Lane, Rockville, 1993, s. 90.
86. Mravčík, V., Korčíšová, B., Lejčková, P., Miovská, L., Škrdlantová, E., Petroš, O., Raňmecký, J., Sklenář, V., Gajdošíková, H., Vopravil, J.: Výroční zpráva o stavu ve věcech drog v České republice v roce 2003, Praha.
87. Naeye, R.L., Blanc, W., Leblanc, W., Khatamee, M.A.: Fetal complications of maternal heroin addiction: Abnormal growth, infections, and episodes of stress. *The Journal of Pediatrics*, 83, 6, 1973, s. 1055–1061.
88. Nair, P., Rothblum, S., Hebel, R.: Neonatal Outcome in infants with evidence of fetal exposure to opiates, cocaine and cannabinoids. *Clinical pediatrics*, 3, 1994, s. 280–285.
89. Nair, P.: Pharmacological management of neonatal opioid abstinence syndrome. *CNS Drugs* 8, 161, 12, 1997, s. 448–456.
90. Ornoy, A.: The effects of alcohol and illicit drugs on the human embryo and fetus. *Isr J Psychiatry Relat Sci* 2002;39(2), s. 120–132.
91. Oro, A.S., Dixon, S.D.: Perinatal cocaine and methamphetamine exposure: Maternal and neonatal correlates. *The Journal of Pediatrics*, 111, 4, 1987, s. 571–578.
92. Ostrea, E.M., Chavez, C.: Perinatal problems (excluding neonatal withdrawal) in maternal drug addiction: A study of 830 cases. *J Pediatr*, 94, 1979, s. 292–295.
93. Ostrea, E.M. jr., Brady, M.J., Parks, P.M. et al.: Drug screening of meconium in infants of drug-dependent mothers: An alternative to urine testing. *J Pediatr* 115, 1989, s. 474.
94. Pantuck, E.J., Pantuck, C.B., Ryan, D.E. et al.: Inhibition and stimulation of enflurane metabolism in the rat following a single dose or chronic administration of ethanol. *Anesthesiology*, 62, 1985, s. 255.
95. Parrino, M.W.: State Methadon Treatment Guidelines, Treatment Improvement Protocol TIP Series, 1 Fishers Lane, Rockville, 1993, s. 222.
96. Perlow, J., Schlossberg, D., Strassner, H.: Intrapartum Cocaine Use. *J of Reproductive Medicine*, 35, 10, 1990, s. 978–980.
97. Plessinger, A.M.: Prenatal exposure to amphetamines. In: *Obstetrics and Gynecology of North America, Substance Abuse in Pregnancy*, Philadelphia, W.B.Saunders, 1998, s. 119–138.
98. Plessinger, M.A., Woods, J.R. jr.: Maternal, placental, and fetal pathophysiology of cocaine exposure during pregnancy. *Clin Obstet Gynecol*, 36, 2, s. 267–278.
99. Robe, L.B., Gromisch, D.S., Iosub, S.: Symptoms of neonatal ethanol withdrawal. *Curr Alcohol* 1981, 8, s. 485–93.
100. Rosen, T.S.: Infant of addicted Mothers. *Clinics in Perinatology* 176, 6, 1997, s. 672–682.
101. Rybka, J. a kol.: Kritické stavy vnitřního lékařství ve všeobecné praxi, Avicenum, Praha, 1992.
102. Sancewitz-Pach, K., Chmiest, W., Lichota, E.: Suicidal paracetamol poisoning of a pregnant woman just before a delivery., *Przegl Lek* . 1999, 56 (6), s. 459–62.

103. *Sastry, B.V.R., Mouton, S., Janson, V.E.:* Tobacco smoking by pregnant women: Disturbances in metabolism of branched chain amino acids and fetal growth. *Am NY Acad Sci*, 678, 1989, s. 361.
104. *Schottenfeld, R., Pakes, J., Kosten, T.:* Prognostic Factors in Buprenorphine versus Methadon – Maintained Patients. *The Journal of Nervous and Mental Disease*, 186, 1998, 1, s. 35–43.
105. *Šejda, J., Studničková, B., Klepetková, M., Šeblová, J., Hančlová, H.:* Epidemiologie drog a uživatelů drog – Česká republika 1999, 2, 2000, s. 1–134.
106. *Shiono, P. et al.:* The impact of cocaine and marijuana use on low birth weight and preterm birth: A multicenter study. *Am J Obstet Gynecol*, 172, 1, 1995, s. 19–27.
107. *Singer, L., Arendt, R., Li Yu Song, M., Warshawsky, E., Kliegman, R.:* Direct and Indirect Interactions of Cocaine with Childbirth Outcomes. *Arch Pediatr Adolesc. Med*, 148, 9, 1994, s. 959–964.
108. *Sloan, L.B., Gay, J.W., Snyder, S.W. et al.:* Substance abuse during pregnancy in a rural population. *Obstet Gynecol*, 79, 1992, s. 245. Úřad vlády ČR, 2004.
109. *Stec, A.M., Fisher, B.K., Baker, R.S. et al.:* Maternal and fetal cardiovascular responses to methamphetamine in pregnant sheep. *Am J Obstet Gynecol*, 169, 1993, s. 888.
110. *Stocker, S.:* Men and women in drug abuse treatment relapse at different rates and for different reasons. *National Inst Drug Abuse Notes*, 13, 1998, s. 5–6.
111. *Sutton, L.R., Hinderliter, S.A.:* Diazepam abuse in pregnant women on methadone maintenance: Implications for the neonate. *Clin Pediatr*, 29, 1990, s. 108.
112. *Tabor, B.L., Smith-Wallace, T., Yonekura, M.L.:* Perinatal outcome associated with PCP versus cocaine use. *Am J Drug Alcohol Abuse*. 1990, 16 (3–4), s. 337–48.
113. *Tronick, E., Beeghly, M.:* Prenatal cocaine exposure, child development, and the compromising effects of cumulative risk. *Clinics in Perinatology*, 26, 1, 1999, 3, s. 151–171.
114. *Tronick, E., Frank, D., Cabral, H., Mirochnik, M., Zuckerman, B.:* Late dose response effects of prenatal cocaine exposure on newborn neurobehavioral performance. *Pediatrics*, 98, 1, 1996, s. 76–83.
115. *Valimaki, M. et al.:* Serum lipids and lipoproteins in alcoholic woman during pregnancy. *Metabolism* 1990 May;39(5), s. 486–93.
116. *Van Baar, A., de Graaff, B.M.T.:* Cognitive development and preschool-age of infants of drug – dependent mothers. *Dev Med Child Neuro*, 36, 1994, s. 1063–1075.
117. *Vaughn, A.J., Carzoli, R.P., Sanchez-Ramos, L. et al.:* Community-wide estimation of illicit drug use in delivering women: Prevalence, demographics, and associated risk factors. *Obstet Gynecol*, 82, 92, 1993.
118. *Vinik, H.R., Bradley, E.L., Kisen, I.:* Midazolam-fentanyl synergism for anesthetic induction in patients. *Anesthesiology*, 69, 1989, s. 213.
119. *Volkow, N.D., Wang, G.J., Fowler, J.S., Legan, J., Gatley, S.J., Hitzeman, R., Chen, A.*

- D., Deweey, S.L., Pappas, N.: Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. *Nature*, 386, 1997, s. 830–833.
120. Volpe, J.J.: Effect of Cocain Use on the Fetus. *The New Engl. J. of Med.* 327, 1992, 6, s. 399–407.
121. Volpe, J.J.: *Neurology of the Newborn*, 3-rd ed. WB Saunders, Philadelphia, 1995, s. 765.
122. Wagner, C.L., Katikaneni, L.D., Cox, T.H., Ryan, R.M.: The impact of prenatal Drug exposure on the Neonate. In: *Obstetrics and Gynecology of North America. Substance Abuse in Pregnancy*, Philadelphia, W.B. Saunders, 1998, s. 169–195.
123. Webeh, H., Matthews, R.P., McCalla, S., Feldman, J., Minkoff, H.L.: The effect of recent cocaine use on the progress of labor. *Am J Obstet Gynecol*, 172, 3, 1995, s. 1014–1018.
124. Weinbroum, A.A., Flaishon, R., Sorkine, P., Szold, O., Rudick, V.: A risk – benefit assesement of flumazenil in the management of benzodiazepine overdose. *Drug Saf.* 1997 Sep, 17 (3), s. 181–96.
125. Wilson, G.S., McCreary, R., Kean, J. et al.: The development of preschool children of heroin-addicted mothers: A controlled study. *Pediatrics*, 63, 1979 s. 135–141.
126. Woods, J.R.: Substance Abuse in pregnancy. *Obstetrics and Gynecology clinics of North Amerika*, Saunders, Philadelphia, 25, 1, 1998, s. 272.
127. Yersin, B.: [Ambulatory management of alcohol withdrawal syndrome]. *Schweiz Rundsch Med Prax.* 1999 Oct 14;88(42), s. 1705–9.
128. Zuckerman, B., Frank, D.A., Hingson, R., Amaro, H., Levenson, S.M. et al.: Effect of maternal marijuana and cocaine use on fetal growth. *The New Engl. J. of Med.* 320, 12, 1989, s. 762–768.